Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEXAR study of bexmarilimab + doxorubicin in metastatic soft tissue sarcoma
2025-525144-18-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bexmarilimab and doxorubicin in soft tissue sarcoma (STS) (3 arms), sponsored by MEDSIR. Primary endpoints: Maximum tolerated dose and recommended phase II dose and Progression-free survival. Planned start Jul 2026; status: authorised.
02
Drugs
bexmarilimabdoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2025-525144-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525144-18-00.